In the first quarter of 2024, the Genomics/NGS group reported higher sales of universal library prep kits for use with third-party next-generation sequencers. The QDI business continued to see solid demand trends, setting out an optimistic CER growth outlook for the full year. Furthermore, QIAGEN continuously integrates AI technology into the QDI portfolio, launching an AI-driven knowledge base for drug discovery and enhancing QCI Interpret software for rare disease gene coverage. Strategic Collaborations t ...

QIAGEN N.V. (QGEN) recently announced the receipt of the European Union (EU) Technical Documentation Assessment and Quality Management System certificate under the European In Vitro Diagnostic Medical Device Regulation for its updated version of its clinical decision support platform — QIAGEN Clinical Insight (QCI) Interpret. The recent regulatory approval ensures greater patient protection, transparency of information and traceability of data. For investors' note, QCI Interpret is a software that aids in i ...

QIAGEN N.V. (QGEN) recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the test is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets.The latest development will strongly boost the company’s Molecular Diagnostics business.Significance of the QIAstat-Dx Respiratory Panel PlusR ...

QIAGEN N.V. (QGEN) recently entered into a cooperative research and development agreement (CRADA) with the Federal Bureau of Investigation (FBI). The deal advances a novel test for its QIAcuity digital PCR devices that will enhance forensics by improving the quantification of DNA in human samples. The recent development will strengthen QIAGEN's leading position in the human identification (HID) and forensics business. More on the News As a federally accredited laboratory, the FBI performs research and devel ...

Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat-Dx Respiratory Panel Plus is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. It was previously authorized under a U.S. FDA Emergency ...

Have you evaluated the performance of Qiagen's (QGEN) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this diagnostic products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth j ...

Exhibit 99.1 U.S. GAAP Quarterly Report for the Period Ended March 31, 2024 Table of Contents Condensed Consolidated Financial Statements 28 Operating and Financial Review and Prospects 2 Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Income (unaudited) for the three months ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three months ended March 31, 2024 and 2023 ...

Your contacts Coordinator Investor Relations | --- | --- | |--------------------------------------|---------------| | Analyst and Investor Day (New York) | June 17, 2024 | | Annual General Meeting | June 21, 2024 | | Q2 2024 results | July 2024 | Internet: corporate.QIAGEN.com www.x.com/QIAGEN | --- | --- | --- | |---------------------------------------------------------------|-------------------|-------------------| | Three months ended (In $ thousands) | March 31, 2024 | March 31, 2023 | | Cash flows from ...

Financial Data and Key Metrics Changes - QIAGEN reported net sales of $462 million at constant exchange rates (CER), exceeding the outlook of at least $455 million CER, representing a 5% decline from Q1 2023 [12][83] - Adjusted earnings per share (EPS) were $0.47 at CER, ahead of the outlook for at least $0.44 CER [13][86] - Adjusted operating income margin was 25.7%, slightly up from 25.6% in Q1 2023, despite a 5% decline in adjusted operating income to $118 million [64][85] Business Line Data and Key Metrics Changes - Diagnostic Solutions product group achieved 5% CER growth, with double-digit sales growth for QuantiFERON TB test and QIAstat syndromic testing system [12][68] - Consumables and related revenues experienced a 4% CER decline, while instrument sales declined 9% CER due to a challenging capital purchase environment [67] - QIAcuity digital PCR system delivered solid double-digit CER growth, driven by increased demand for biopharma applications [63][71] Market Data and Key Metrics Changes - Sales in the Americas were impacted by COVID headwinds, but demand for QuantiFERON, QIAstat, and QIAcuity consumables improved [73] - Europe, Middle East, and Africa region saw a 2% CER decline, but underlying results rose at a single-digit CER rate excluding pandemic impacts [73] - In the Asia Pacific region, sales in China declined at a double-digit CER rate, while improved results were noted in India and South Korea [74] Company Strategy and Development Direction - QIAGEN is focused on a balanced and strategic approach to growth, emphasizing the importance of recurring consumable sales, which account for over 85% of total net sales [12][111] - The company plans to continue investing in R&D and commercialization initiatives while monitoring market conditions closely [94][101] - QIAGEN aims to achieve at least $2 billion in net sales for 2024, with a focus on mid-single-digit growth in the second half of the year [92][94] Management's Comments on Operating Environment and Future Outlook - Management noted a cautious capital spending environment among customers but expressed confidence in achieving 2024 goals [11][12] - The company does not expect a rebound in the Chinese market until at least 2025, maintaining a conservative outlook for that region [49][145] - Management highlighted ongoing high levels of profitability and efficiency gains, with expectations for adjusted operating income margin to reach at least 28% for 2024 [64][94] Other Important Information - Free cash flow rose nearly 1.5 times to $97 million compared to Q1 2023, with a slight increase in investments in property and equipment [75] - The liquidity position was approximately $893 million at the end of Q1 2024, down from $1.1 billion at the end of 2023, influenced by a $300 million cash payout for share repurchase [76][88] - QIAGEN is actively exploring targeted acquisitions to complement its portfolio while prioritizing organic growth [101][124] Q&A Session Summary Question: What is the outlook for QuantiFERON growth throughout the year? - Management indicated that QuantiFERON typically accelerates in Q3 and Q4, with ongoing initiatives supporting this growth [113] Question: What are the capital allocation priorities for the year? - The company prioritizes organic investment in R&D, potential accretive acquisitions, and returning value to shareholders through share buybacks [123][124] Question: How does QIAGEN view the recent FDA ruling on lab-developed tests? - Management stated that QIAGEN's exposure to LDTs is limited, and the ruling may reinforce the company's position in supplying quality control components [129]

QIAGEN N.V.’s (QGEN) first-quarter 2024 adjusted earnings per share (EPS) were 46 cents and 47 cents at constant exchange rate (CER), down 9.8% year over year. However, the figure topped the Zacks Consensus Estimate by 4.6%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 36 cents, down 2.7% ...